Private drug plans in Canada: H82-26/2016-PDF
high-cost drugs and beneficiaries, 2005 to 2015 = Régimes privés d’assurance-médicaments au Canada : médicaments et bénéficiaires à coûts élevés, de 2005 à 2015.
"The increased availability and use of high-cost drugs has been fueling the recent growth in drug expenditures in Canada, raising concerns over the sustainability of private drug plans. This upcoming PMPRB study provides insight into the impact of high-cost beneficiaries and drugs on private plan expenditures. The results indicate that beneficiaries and drugs costing in excess of $10,000 per year represent a growing market segment with important implications on drug expenditure levels. The analysis uses the IMS Brogan® Private Drug Plan Database for the period from 2005 to 2015. This is one of three reports in a PMPRB series that analyzes the trends in Canadian private drug plans. This series provides policy makers and other stakeholders with valuable insights into the sources of cost pressures in private drug plans and supports them in predicting future trends and identifying cost-saving opportunities."
|Department/Agency||Patented Medicine Prices Review Board.|
|Title||Private drug plans in Canada|
|Subtitle||high-cost drugs and beneficiaries, 2005 to 2015 = Régimes privés d’assurance-médicaments au Canada : médicaments et bénéficiaires à coûts élevés, de 2005 à 2015.|
|Language||Bilingual-[English | French]|
|Electronic Document|| |
Note: The URLs contained in this/these document(s) may no longer be functional
|Note||Caption title. At head of title: National Prescription Drug Utilization Information System.|
|Number of Pages|| p. :|
|Subject Terms||Drug insurance, Prescription drugs, Prices|
- Date modified: